Navigation Links
500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
Date:5/28/2009

BERLIN, May 28 /PRNewswire/ -- The 500th patient was supported with the Berlin Heart EXCOR(R) Pediatric Ventricular Assist Device (also known as the "Berlin Heart") since the first implantation of the device in 1990. The patient, an 11-month-old girl, received the device at the Children's Memorial Hospital in Chicago and has been successfully transplanted in the meantime.

Alejandra had been diagnosed a few weeks after birth with left ventricular non compaction and dilative cardiomyopathy, a disease that causes the heart muscle to enlarge and weaken. From six months of age, she received medications for her heart disease, but as she progressively worsened, she had to be placed on the waiting list for a donor heart. She presented to Dr. Elfriede Pahl, medical director of heart transplantation at Children's Memorial Hospital, with a respiratory infection and required mechanical ventilation.

Alejandra was placed on ECMO, a modified version of a heart-lung machine, on 2 January 2009, but rapidly deteriorated. "She was difficult to support on ECMO with a good deal of bleeding and relatively poor systemic perfusion," recalls Dr. Jeffrey Gossett, Alejandra's cardiologist. "As a result we needed to continue paralysis and were unable to feed her well."

By the time she received the Berlin Heart EXCOR Pediatric VAD, she had spent 38 days on mechanical ventilation and three days on ECMO. Alejandra's mother recalls, "We were devastated and very anxious. We had to hope for a miracle to help Alejandra."

    Full story under:
http://www.berlinheart.com/500th_EXCOR_Pediatric_Patient_full_story.pdf

Pictures available.

About EXCOR(R) Pediatric

The EXCOR Pediatric Ventricular Assist Device is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. EXCOR Pediatric has been used in more than 500 pediatric patients worldwide ranging from newborns with 2.2 kg body weight to teenagers. EXCOR is currently under clinical investigation for pediatric patients in USA.

About Berlin Heart

Berlin Heart GmbH is the only company worldwide that develops, produces, and distributes implantable and external ventricular assist devices (also called mechanical heart support systems) for patients of every age and body size. The company is market leader in Germany and Europe.

The company also manufactures the implantable left ventricular assist device INCOR(R), which has been designed for long-term application in adult patients. The longest the device has supported a patient so far is more than five and a half years and ongoing. INCOR is not FDA approved, but widely used in Europe.

    Contact:

    Linda Buerk
    Manager Marketing & PR
    Phone: +49(0)30-8187-2650
    Mobile: +49(0)173-629-0803
    buerk@berlinheart.de



'/>"/>
SOURCE Berlin Heart GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Plexon Inc Delivers 500th "Harvey Box" : 25 Years of Neural Data Acquisition and Analysis Leads to 500th System Sale
2. Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation
3. SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System
4. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
5. Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22
6. VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
7. Adipose-derived Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Groups, Entest BioMedical Inc. Researcher
8. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
9. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
10. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
11. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Biostage, Inc. (Nasdaq: ... developing bioengineered organ implants to treat cancers and other ... today the closing on February 15, 2017 of its ... stock and warrants to purchase 20,000,000 shares of common ... offering was priced at $0.40 per share of common ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... Series 1a financing and entered into a $5 ...  Dermata intends to use the capital for general ... major advancements in the treatment of serious diseases ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... extended its industry leading Biochemistry Services specifically targeting the rapidly growing needs ... methods for the biochemical and biosimilar characterization , product-related impurity characterization, ...
Breaking Biology Technology:
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
Breaking Biology News(10 mins):